BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a leading lung cancer diagnostic solutions company, today announced the appointment of Charles Watts, M.D. to the company’s board of directors. Dr. Watts’ clinical career as a pulmonology-critical care specialist expands on the company’s expertise in pulmonology and supports the corporate mission of improving every patient’s lung cancer care by empowering physicians with swift, comprehensive, and actionable insights.
Dr. Watts served as Chief Medical Officer at Northwestern Memorial Hospital and Associate Dean for Clinical Affairs at the Feinberg School of Medicine, where he was nationally recognized for his work championing patient safety. Currently, he is an emeritus professor of medicine at Northwestern University. Dr. Watts has also served as Chief of Clinical Affairs and Associate Dean at the University of Michigan Medical Center, Director of Providence Health and Services in Washington, and Chief Medical Officer for Swedish Health Services in Seattle. He serves on the board of the Institute for Systems Biology and as a trustee and board member for several organizations and institutions focused on public health. Dr. Watts received his degrees and training in pulmonology and critical care at the University of Michigan.
“Dr. Watts’ dedication to improving outcomes, as a pulmonologist and a healthcare leader, are consistent with our mission and a great asset,” said David Brunel, Biodesix CEO. “His keen interest in advancing the use of proteomics and genomics in routine treatment, highlighted by his engagement with the Institute for Systems Biology, reflects our founding principles of bringing multi-omics into the clinic. Dr. Watts brings extensive and valuable experience to our Board.”
Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ and EarlyCDT Lung® nodule tests, evaluate the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.